{"id":30879,"date":"2026-06-13T11:40:34","date_gmt":"2026-06-13T03:40:34","guid":{"rendered":"https:\/\/shchimay.com\/pharmaceutical-water-systems-under-fda-scrutiny-building-compliance-ready-monitoring-infrastructure\/"},"modified":"2026-06-13T11:40:34","modified_gmt":"2026-06-13T03:40:34","slug":"pharmaceutical-water-systems-under-fda-scrutiny-building-compliance-ready-monitoring-infrastructure","status":"publish","type":"post","link":"https:\/\/shchimay.com\/ja\/pharmaceutical-water-systems-under-fda-scrutiny-building-compliance-ready-monitoring-infrastructure\/","title":{"rendered":"Pharmaceutical Water Systems Under FDA Scrutiny: Building Compliance-Ready Monitoring Infrastructure"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_50 counter-hierarchy ez-toc-counter ez-toc-light-blue ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/shchimay.com\/ja\/pharmaceutical-water-systems-under-fda-scrutiny-building-compliance-ready-monitoring-infrastructure\/#Pharmaceutical_Water_Systems_Under_FDA_Scrutiny_Building_Compliance-Ready_Monitoring_Infrastructure\" title=\"Pharmaceutical Water Systems Under FDA Scrutiny: Building Compliance-Ready Monitoring Infrastructure\">Pharmaceutical Water Systems Under FDA Scrutiny: Building Compliance-Ready Monitoring Infrastructure<\/a><ul class='ez-toc-list-level-2'><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/shchimay.com\/ja\/pharmaceutical-water-systems-under-fda-scrutiny-building-compliance-ready-monitoring-infrastructure\/#Introduction\" title=\"Introduction\">Introduction<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/shchimay.com\/ja\/pharmaceutical-water-systems-under-fda-scrutiny-building-compliance-ready-monitoring-infrastructure\/#Understanding_Regulatory_Expectations\" title=\"Understanding Regulatory Expectations\">Understanding Regulatory Expectations<\/a><ul class='ez-toc-list-level-3'><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/shchimay.com\/ja\/pharmaceutical-water-systems-under-fda-scrutiny-building-compliance-ready-monitoring-infrastructure\/#FDA_Water_System_Compliance_Framework\" title=\"FDA Water System Compliance Framework\">FDA Water System Compliance Framework<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/shchimay.com\/ja\/pharmaceutical-water-systems-under-fda-scrutiny-building-compliance-ready-monitoring-infrastructure\/#Common_Regulatory_Findings\" title=\"Common Regulatory Findings\">Common Regulatory Findings<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/shchimay.com\/ja\/pharmaceutical-water-systems-under-fda-scrutiny-building-compliance-ready-monitoring-infrastructure\/#Building_a_Compliance-Ready_Infrastructure\" title=\"Building a Compliance-Ready Infrastructure\">Building a Compliance-Ready Infrastructure<\/a><ul class='ez-toc-list-level-3'><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/shchimay.com\/ja\/pharmaceutical-water-systems-under-fda-scrutiny-building-compliance-ready-monitoring-infrastructure\/#Multi-Layered_Monitoring_Architecture\" title=\"Multi-Layered Monitoring Architecture\">Multi-Layered Monitoring Architecture<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/shchimay.com\/ja\/pharmaceutical-water-systems-under-fda-scrutiny-building-compliance-ready-monitoring-infrastructure\/#Data_Management_Requirements\" title=\"Data Management Requirements\">Data Management Requirements<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/shchimay.com\/ja\/pharmaceutical-water-systems-under-fda-scrutiny-building-compliance-ready-monitoring-infrastructure\/#Compliance_Documentation_Framework\" title=\"Compliance Documentation Framework\">Compliance Documentation Framework<\/a><ul class='ez-toc-list-level-3'><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/shchimay.com\/ja\/pharmaceutical-water-systems-under-fda-scrutiny-building-compliance-ready-monitoring-infrastructure\/#Validation_Documentation_Package\" title=\"Validation Documentation Package\">Validation Documentation Package<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/shchimay.com\/ja\/pharmaceutical-water-systems-under-fda-scrutiny-building-compliance-ready-monitoring-infrastructure\/#Ongoing_Compliance_Maintenance\" title=\"Ongoing Compliance Maintenance\">Ongoing Compliance Maintenance<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/shchimay.com\/ja\/pharmaceutical-water-systems-under-fda-scrutiny-building-compliance-ready-monitoring-infrastructure\/#Risk_Assessment_Approach\" title=\"Risk Assessment Approach\">Risk Assessment Approach<\/a><ul class='ez-toc-list-level-3'><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/shchimay.com\/ja\/pharmaceutical-water-systems-under-fda-scrutiny-building-compliance-ready-monitoring-infrastructure\/#ICH_Q9_Quality_Risk_Management\" title=\"ICH Q9 Quality Risk Management\">ICH Q9 Quality Risk Management<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/shchimay.com\/ja\/pharmaceutical-water-systems-under-fda-scrutiny-building-compliance-ready-monitoring-infrastructure\/#Technology_Selection_Criteria\" title=\"Technology Selection Criteria\">Technology Selection Criteria<\/a><ul class='ez-toc-list-level-3'><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/shchimay.com\/ja\/pharmaceutical-water-systems-under-fda-scrutiny-building-compliance-ready-monitoring-infrastructure\/#Compliance_Capability_Evaluation\" title=\"Compliance Capability Evaluation\">Compliance Capability Evaluation<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/shchimay.com\/ja\/pharmaceutical-water-systems-under-fda-scrutiny-building-compliance-ready-monitoring-infrastructure\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h1 id=\"pharmaceutical-water-systems-under-fda-scrutiny-building-compliance-ready-monitoring-infrastructure\"><span class=\"ez-toc-section\" id=\"Pharmaceutical_Water_Systems_Under_FDA_Scrutiny_Building_Compliance-Ready_Monitoring_Infrastructure\"><\/span>Pharmaceutical Water Systems Under FDA Scrutiny: Building Compliance-Ready Monitoring Infrastructure<span class=\"ez-toc-section-end\"><\/span><\/h1>\n<p><strong>Key Takeaways:<\/strong><br \/>\n&#8211; <strong>FDA<\/strong> warning letters citing water system deficiencies increased <strong>34%<\/strong> between 2019-2024, with monitoring system inadequacies as primary findings<br \/>\n&#8211; Continuous monitoring systems with <strong>electronic signatures<\/strong> and <strong>audit trails<\/strong> address <strong>21 CFR Part 11<\/strong> requirements that appear in <strong>67%<\/strong> of regulatory observations<br \/>\n&#8211; Pharmaceutical facilities investing in comprehensive monitoring infrastructure achieve <strong>89% fewer<\/strong> water-related regulatory deviations<br \/>\n&#8211; <strong>Shanghai ChiMay<\/strong> <a href=\"\/tag\/water-quality-analyzer\" target=\"_blank\"><strong>water quality analyzer<\/strong><\/a> solutions provide complete <strong>audit-ready documentation packages<\/strong> aligned with FDA, EMA, and WHO prequalification requirements<\/p>\n<h2 id=\"introduction\"><span class=\"ez-toc-section\" id=\"Introduction\"><\/span>Introduction<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The pharmaceutical industry operates under unprecedented regulatory scrutiny. Water systems\u2014the foundation of pharmaceutical manufacturing\u2014face particularly intense review during regulatory inspections. Recent <strong>FDA<\/strong> enforcement data reveals that water quality monitoring deficiencies appear in approximately <strong>28%<\/strong> of all <strong>Form 483 observations<\/strong> issued to pharmaceutical manufacturers, making water system compliance one of the highest-priority quality system concerns.<\/p>\n<p><strong>Critical context:<\/strong> The <strong>European Medicines Agency (EMA)<\/strong> reported similar patterns in <strong>GMP<\/strong> inspections, with water system observations increasing <strong>22%<\/strong> year-over-year as regulators implement stricter data integrity enforcement under <strong>EudraLex Volume 4<\/strong> guidelines.<\/p>\n<h2 id=\"understanding-regulatory-expectations\"><span class=\"ez-toc-section\" id=\"Understanding_Regulatory_Expectations\"><\/span>Understanding Regulatory Expectations<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3 id=\"fda-water-system-compliance-framework\"><span class=\"ez-toc-section\" id=\"FDA_Water_System_Compliance_Framework\"><\/span>FDA Water System Compliance Framework<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>FDA<\/strong> expects pharmaceutical manufacturers to implement water monitoring programs that demonstrate:<\/p>\n<p><strong>Design qualification (DQ):<\/strong> Water systems must be designed to consistently produce water meeting pharmacopeial specifications. This includes appropriate monitoring point selection, sensor specifications, and data collection capabilities.<\/p>\n<p><strong>Installation\/operational qualification (IQ\/OQ):<\/strong> Monitoring equipment must be installed, calibrated, and operated according to validated procedures. Documentation must demonstrate that all monitoring activities conform to approved specifications.<\/p>\n<p><strong>Performance qualification (PQ):<\/strong> Ongoing monitoring must demonstrate that the water system consistently produces acceptable water under all expected operating conditions. Statistical analysis of monitoring data provides evidence of system performance.<\/p>\n<p><strong>Continuous monitoring verification:<\/strong> Real-time monitoring systems must provide equivalent or superior data quality compared to traditional laboratory testing. <strong>FDA<\/strong> guidance explicitly encourages continuous monitoring as a preferred compliance approach.<\/p>\n<h3 id=\"common-regulatory-findings\"><span class=\"ez-toc-section\" id=\"Common_Regulatory_Findings\"><\/span>Common Regulatory Findings<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Analysis of recent <strong>FDA<\/strong> warning letters and <strong>483 observations<\/strong> reveals recurring themes:<\/p>\n<table>\n<thead>\n<tr>\n<th>Observation Category<\/th>\n<th>Frequency<\/th>\n<th>Primary Cause<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Inadequate monitoring frequency<\/td>\n<td>35%<\/td>\n<td>Manual vs. continuous systems<\/td>\n<\/tr>\n<tr>\n<td>Calibration deficiencies<\/td>\n<td>28%<\/td>\n<td>Missing documentation<\/td>\n<\/tr>\n<tr>\n<td>Alarm response failures<\/td>\n<td>22%<\/td>\n<td>Integration gaps<\/td>\n<\/tr>\n<tr>\n<td>Data integrity issues<\/td>\n<td>15%<\/td>\n<td>Manual transcription errors<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Key insight:<\/strong> The <strong>Data Integrity Guidance<\/strong> issued by <strong>FDA<\/strong> in 2018 explicitly addresses water monitoring systems, requiring electronic records with complete audit trails and restricted system access\u2014requirements that automated monitoring systems address more effectively than manual processes.<\/p>\n<h2 id=\"building-a-compliance-ready-infrastructure\"><span class=\"ez-toc-section\" id=\"Building_a_Compliance-Ready_Infrastructure\"><\/span>Building a Compliance-Ready Infrastructure<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3 id=\"multi-layered-monitoring-architecture\"><span class=\"ez-toc-section\" id=\"Multi-Layered_Monitoring_Architecture\"><\/span>Multi-Layered Monitoring Architecture<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Modern pharmaceutical water monitoring requires defense-in-depth architecture:<\/p>\n<p><strong>Layer 1: Continuous sensors<\/strong> \u2014 Real-time measurement at critical control points<br \/>\n<strong>Layer 2: Alert systems<\/strong> \u2014 Immediate notification of approaching specification limits<br \/>\n<strong>Layer 3: Laboratory verification<\/strong> \u2014 Periodic confirmation testing per <strong>USP &lt;1230&gt;<\/strong><br \/>\n<strong>Layer 4: Environmental monitoring<\/strong> \u2014 Correlation with facility monitoring programs<\/p>\n<p>This layered approach provides multiple independent evidence sources, addressing regulator expectations for robust quality systems.<\/p>\n<h3 id=\"data-management-requirements\"><span class=\"ez-toc-section\" id=\"Data_Management_Requirements\"><\/span>Data Management Requirements<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>21 CFR Part 11<\/strong> compliance demands specific data management capabilities:<\/p>\n<ul>\n<li><strong>Electronic signatures:<\/strong> Authorized personnel must apply electronic signatures to critical data reviews<\/li>\n<li><strong>Audit trails:<\/strong> All data modifications, deletions, and system events must be logged permanently<\/li>\n<li><strong>Access controls:<\/strong> System access restricted to authorized personnel with role-based permissions<\/li>\n<li><strong>Archive capabilities:<\/strong> Data retention per product lifecycle requirements (typically <strong>5 years minimum<\/strong>)<\/li>\n<\/ul>\n<p><strong>Shanghai ChiMay<\/strong> <a href=\"\/tag\/water-quality-analyzer\" target=\"_blank\"><strong>water quality analyzer<\/strong><\/a> platforms incorporate these capabilities natively, with <strong>SQL database architecture<\/strong> supporting <strong>21 CFR Part 11<\/strong> compliance requirements and seamless integration with <strong>SAP<\/strong>, <strong>Veeva<\/strong>, and other pharmaceutical quality management systems.<\/p>\n<h2 id=\"compliance-documentation-framework\"><span class=\"ez-toc-section\" id=\"Compliance_Documentation_Framework\"><\/span>Compliance Documentation Framework<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3 id=\"validation-documentation-package\"><span class=\"ez-toc-section\" id=\"Validation_Documentation_Package\"><\/span>Validation Documentation Package<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Regulatory submissions require comprehensive validation documentation:<\/p>\n<ol>\n<li><strong>Validation plan<\/strong> defining scope, approach, and acceptance criteria<\/li>\n<li><strong>Design qualification<\/strong> documenting system specifications and supplier verification<\/li>\n<li><strong>Installation qualification<\/strong> verifying proper installation per design specifications<\/li>\n<li><strong>Operational qualification<\/strong> confirming performance against acceptance criteria<\/li>\n<li><strong>Performance qualification<\/strong> demonstrating ongoing suitability for intended use<\/li>\n<\/ol>\n<p><strong>Industry benchmark:<\/strong> Companies maintaining complete validation packages experience <strong>45% fewer<\/strong> regulatory findings during inspections, according to <strong>Pharmaceutical Engineering<\/strong> magazine survey data.<\/p>\n<h3 id=\"ongoing-compliance-maintenance\"><span class=\"ez-toc-section\" id=\"Ongoing_Compliance_Maintenance\"><\/span>Ongoing Compliance Maintenance<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Continuous compliance requires systematic maintenance activities:<\/p>\n<table>\n<thead>\n<tr>\n<th>Activity<\/th>\n<th>Frequency<\/th>\n<th>Responsible Party<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Calibration verification<\/td>\n<td>Monthly<\/td>\n<td>Quality Control<\/td>\n<\/tr>\n<tr>\n<td>Sensor performance review<\/td>\n<td>Quarterly<\/td>\n<td>Engineering<\/td>\n<\/tr>\n<tr>\n<td>System audit trail review<\/td>\n<td>Monthly<\/td>\n<td>Quality Assurance<\/td>\n<\/tr>\n<tr>\n<td>Regulatory intelligence<\/td>\n<td>Ongoing<\/td>\n<td>Regulatory Affairs<\/td>\n<\/tr>\n<tr>\n<td>SOP updates<\/td>\n<td>As needed<\/td>\n<td>Document Control<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 id=\"risk-assessment-approach\"><span class=\"ez-toc-section\" id=\"Risk_Assessment_Approach\"><\/span>Risk Assessment Approach<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3 id=\"ich-q9-quality-risk-management\"><span class=\"ez-toc-section\" id=\"ICH_Q9_Quality_Risk_Management\"><\/span>ICH Q9 Quality Risk Management<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Per <strong>ICH Q9<\/strong> guidelines, pharmaceutical water monitoring risk assessments should evaluate:<\/p>\n<p><strong>Patient safety risks:<\/strong> Water quality excursions affecting product quality<br \/>\n<strong>Regulatory risks:<\/strong> Non-compliance with pharmacopeial requirements<br \/>\n<strong>Operational risks:<\/strong> Production disruptions from monitoring-related investigations<\/p>\n<p><strong>Risk scoring matrix:<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Risk Factor<\/th>\n<th>High<\/th>\n<th>Medium<\/th>\n<th>Low<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Probability of detection<\/td>\n<td>Delayed<\/td>\n<td>Delayed<\/td>\n<td>Immediate<\/td>\n<\/tr>\n<tr>\n<td>Severity of impact<\/td>\n<td>Critical<\/td>\n<td>Moderate<\/td>\n<td>Minor<\/td>\n<\/tr>\n<tr>\n<td>Detectability<\/td>\n<td>Difficult<\/td>\n<td>Moderate<\/td>\n<td>Easy<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>High-risk monitoring points require enhanced controls including redundant sensors, increased monitoring frequency, and comprehensive alarm response procedures.<\/p>\n<h2 id=\"technology-selection-criteria\"><span class=\"ez-toc-section\" id=\"Technology_Selection_Criteria\"><\/span>Technology Selection Criteria<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3 id=\"compliance-capability-evaluation\"><span class=\"ez-toc-section\" id=\"Compliance_Capability_Evaluation\"><\/span>Compliance Capability Evaluation<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>When evaluating water monitoring technology, compliance teams should assess:<\/p>\n<ol>\n<li><strong>Regulatory acceptance history:<\/strong> Number of successful regulatory submissions incorporating the technology<\/li>\n<li><strong>Documentation quality:<\/strong> Completeness and audit-readiness of validation packages<\/li>\n<li><strong>Integration capability:<\/strong> Compatibility with quality management and batch record systems<\/li>\n<li><strong>Support infrastructure:<\/strong> Geographic coverage and regulatory expertise of supplier<\/li>\n<\/ol>\n<p><strong>Shanghai ChiMay<\/strong> has supported <strong>200+<\/strong> pharmaceutical water system validations globally, with documented acceptance by <strong>FDA<\/strong>, <strong>EMA<\/strong>, <strong>PMDA<\/strong>, and <strong>NMPA<\/strong> inspectors. The comprehensive validation documentation package includes:<\/p>\n<ul>\n<li>Risk assessment templates aligned with <strong>ICH Q9<\/strong><\/li>\n<li>IQ\/OQ\/PQ protocols with pre-approved acceptance criteria<\/li>\n<li>Calibration procedures per <strong>USP &lt;1230&gt;<\/strong><\/li>\n<li>Training curriculum for operators and quality personnel<\/li>\n<\/ul>\n<h2 id=\"conclusion\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span>Conclusion<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Building compliance-ready pharmaceutical water monitoring infrastructure requires strategic investment in technology, documentation, and organizational capabilities. Continuous monitoring systems from established suppliers like <strong>Shanghai ChiMay<\/strong> provide the foundation for regulatory success, combining validated equipment performance with comprehensive support services.<\/p>\n<p>Pharmaceutical manufacturers prioritizing water system compliance achieve measurably better regulatory outcomes: <strong>89% fewer<\/strong> water-related deviations, <strong>76%<\/strong> faster audit preparation, and <strong>significantly reduced<\/strong> regulatory risk exposure. In an environment of increasing enforcement intensity, comprehensive water monitoring infrastructure represents both regulatory necessity and competitive advantage.<\/p>\n<hr \/>\n<p><em>Shanghai ChiMay regulatory affairs team provides pre-submission consultation and inspection readiness support for pharmaceutical water monitoring implementations.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pharmaceutical Water Systems Under FDA Scrutiny: Building Compliance-Ready Monitoring Infrastructure Key Takeaways: &#8211; FDA warning letters citing water system deficiencies increased 34% between 2019-2024, with monitoring system inadequacies as primary findings &#8211; Continuous monitoring systems with electronic signatures and audit trails address 21 CFR Part 11 requirements that appear in 67% of regulatory observations &#8211;&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false},"categories":[1],"tags":[154],"translation":{"provider":"WPGlobus","version":"2.12.0","language":"ja","enabled_languages":["en","zh","es","de","fr","ru","pt","ar","ja","ko","it","id","hi","th","vi","tr"],"languages":{"en":{"title":true,"content":true,"excerpt":false},"zh":{"title":false,"content":false,"excerpt":false},"es":{"title":false,"content":false,"excerpt":false},"de":{"title":false,"content":false,"excerpt":false},"fr":{"title":false,"content":false,"excerpt":false},"ru":{"title":false,"content":false,"excerpt":false},"pt":{"title":false,"content":false,"excerpt":false},"ar":{"title":false,"content":false,"excerpt":false},"ja":{"title":false,"content":false,"excerpt":false},"ko":{"title":false,"content":false,"excerpt":false},"it":{"title":false,"content":false,"excerpt":false},"id":{"title":false,"content":false,"excerpt":false},"hi":{"title":false,"content":false,"excerpt":false},"th":{"title":false,"content":false,"excerpt":false},"vi":{"title":false,"content":false,"excerpt":false},"tr":{"title":false,"content":false,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/shchimay.com\/ja\/wp-json\/wp\/v2\/posts\/30879"}],"collection":[{"href":"https:\/\/shchimay.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/shchimay.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/shchimay.com\/ja\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/shchimay.com\/ja\/wp-json\/wp\/v2\/comments?post=30879"}],"version-history":[{"count":0,"href":"https:\/\/shchimay.com\/ja\/wp-json\/wp\/v2\/posts\/30879\/revisions"}],"wp:attachment":[{"href":"https:\/\/shchimay.com\/ja\/wp-json\/wp\/v2\/media?parent=30879"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/shchimay.com\/ja\/wp-json\/wp\/v2\/categories?post=30879"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/shchimay.com\/ja\/wp-json\/wp\/v2\/tags?post=30879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}